

## **MRI DETECTION OF PROSTATE CANCER**

Kamal Mattar MSc MD FRCSC 11<sup>th</sup> Annual Princess Margaret Cancer Centre URO-ONCOLOGY DIALOGUE



## DISCLOSURE

## Advisory board with Astella, Sanofi



## Learning Objectives:

- The role of mp-MRI in the diagnosis of prostate cancer
- Update the evaluation of prostate cancer using mp-MRI
- Review published guidelines and recommendations



# **Prostate Cancer Screening**

#### PSA, DRE and TRUS-GB

**Under-treatment**: miss clinically significant prostate cancers

- low sensitivity and specificity for PCa
- grey- scale ultrasonography fails to distinguish disease
- repeat biopsy yields a diagnosis in 10 -25% in persistent clinical suspicion
- Gleason upgrading in 36% of radical prostatectomy specimens

**Over-treatment**: high rate of over-detection of low risk disease



# **Prostate Cancer Screening**

#### <u>The ideal triage test:</u>


- minimally invasive
- few side effects
- identify men who would benefit from treatment
- overlooks clinically insignificant cancer to minimize over-treatment
- imaging for accurate detection, localization and staging



## multiparametric MRI (mp-MRI)

a. anatomical T2-weighted image low signal intensity, irregular border, ventral transition zone, anterior to BPH nodule
b. diffusion weighted image, functional after iv contrast, cancer shows a lower value, darker than normal tissue
c. diffusion weighted image at high b-values (diffusion effect),

- prostate cancer demonstrates high signal intensity (white)
- d. dynamic contrast enhanced, asymmetric focal enhancement





Masoom A. Haider<sup>1</sup> Theodorus H. van der Kwast<sup>2,3</sup> Jeff Tanguay<sup>2</sup> Andrew J. Evans<sup>2</sup> Ali-Tahir Hashmi<sup>1</sup> Gina Lockwood<sup>4</sup> John Trachtenberg<sup>5</sup>


#### AJR:189, August 2007

### Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer


Performance	W	Whole Prostate						
Measure	T2 Alone	T2 + DWI	p					
Sensitivity	81/149 (54) [44–65]	120/149 (81) [74–86]	< 0.001					
Specificity	222/243 (91) [86–95]	204/243 (84) [77–89]	0.003					
PPV	81/102 (79) [69–87]	120/159 (75) [66–83]	0.29					
NPV	222/290 (77) [69–82]	204/233 (88) [82–92]	< 0.001					
Accuracy	303/392 (77) [72–82]	324/392 (83) [78–86]	0.03					



## **Prostate Cancer:** Value of Multiparametric MR Imaging at 3 T for Detection—Histopathologic Correlation<sup>1</sup>



#### Radiology: Volume 255: Number 1—April 2010



#### Advance in Knowledge

 With combined use of T2-weighted MR imaging with MR spectroscopy and dynamic contrast-enhanced MR imaging at 3 T, a predictive value of 80% can be achieved for prostate cancer detection (P < .05).</li>




European Society of Urogenital Radiology

Clinically significant disease:

- Gleason score  $\geq$  7
- tumour volume >0.5 ml
- and/or extraprostatic extension

#### 39 anatomical locations





### Prostate Imaging Reporting and Data System (PI-RADS)

# 2012 - European Society of Urogenital Radiology (ESUR) published guidelines to standardize evaluation

	Pooled Performar	nce Value (95% CI)		
Studies <sup>a</sup>	Sensitivity	Specificity	Sensitivity	Specificity
All studies	0.74 (0.66–0.81)	0.88 (0.82–0.92)	-	-
Studies that used biopsy as reference standard	0.76 (0.66–0.84)	0.86 (0.79–0.91)	-#-	-
Studies that used prostatectomy as reference standard	0.69 (0.52-0.82)	0.93 (0.81–0.97)		-8
Studies that reported data for the whole gland	0.78 (0.65–0.87)	0.88 (0.80–0.94)		-
Studies that reported data for the peripheral zone	0.81 (0.75–0.85)	0.91 (0.67–0.98)	-	
Studies that reported data by region	0.71 (0.63–0.78)	0.89 (0.83–0.94)	│ , , , , , , , , , , , , , , , , , , ,	
			0.0 0.2 0.4 0.6 0.8 1.0	0.0 0.2 0.4 0.6 0.8 1.0

#### TABLE 7: Forest Plots of Pooled Estimates of All Studies Overall and of Different Subgroups

AJR:202, February 2014



Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis

Sungmin Woo<sup>*a,†*</sup>, Chong Hyun Suh<sup>*b,c,†*</sup>, Sang Youn Kim<sup>*a,\**</sup>, Jeong Yeon Cho<sup>*a,d*</sup>, Seung Hyup Kim<sup>*a,d*</sup> Updated PI-RADSv2 in 2015


Meta-analysis of 21 studies, 3,857 patients

- PIRADS ≥ 4: Sensitivity 89% [86% 92%], Specificity 73% [60% 83%]
- PIRADS ≥ 3: Sensitivity 95% and poor Specificity of 47%
- all studies used PI-RADSv2 strictly according to guidelines
- use of endorectal coil was not a statistically significant factor
- 3 vs. 1.5 T magnet: Sensitivity 90% vs. 89% (p=0.03)



#### Prospective Evaluation of PI-RADS<sup>™</sup> Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System

339 patients with mpMRI, systematic and targeted biopsy PIRADS scoring correlates with cancer detection and Gleason Grade





PCa detection rates by mpMRI in radical prostatectomy specimen

ISUP grade group	Tumour volume (mL)							
	< 0.5	0.5-2	> 2					
ISUP grade 1	21-29%	43-54%	67-75%					
ISUP grade 2-3	63%	82-88%	97%					
ISUP grade $\geq$ 4	80%	93%	100%					


Eur Radiol 2013



## **MRI-TRUS** fusion biopsy

T2-weighted image

Dynamic contrast-enhanced image





Apparent diffusion coefficient image


 B
 MR/ultrasound fusion-guided biopsy showing position of 1 biopsy core

 Real-time axial transrectal ultrasound
 Correlated T2-weighted MRI











Prospective cohort at NCI of patients with elevated PSA and prior negative biopsy underwent targeted and standard 12 core biopsy

1215 Men assessed for eligibility

**181** Men excluded (no lesions on MP-MRI)

1034 Men had MP-MRI lesion biopsied

**31** Excluded (prior treatment)

**1003** Men included in analysis



690 patients (69%) demonstrated agreement between targeted and standard biopsy

Targeted: 30% more high risk & 17% fewer low risk disease

			Standard Extended-Sextant Biopsy Results					
			Low-Risk Cancer		Intermediate-Risk Cancer	High-Risk Cancer		
Targeted MR/Ultrasound Fusion Biopsy Results		No Cancer	Gleason 6	Gleason 3+4 Low Volume <sup>a</sup>	Gleason 3+4 High Volume <sup>b</sup>	Gleason ≥4+3	Totals	
	No cancer	439	74	12	12	5	542	
Low-Risk Cancer	Gleason 6	38	84	12	10	3	147	
	Gleason 3+4 Low volume <sup>c</sup>	17	14	9	19	7	66	
Intermediate-Risk Cancer	Gleason 3+4 High volume <sup>d</sup>	14	21	7	29	4	75	
High-Risk Cancer	Gleason ≥4+3	26	13	12	19	103	173	
	Totals	534	206	52	89	122	1003	



	Whole-Mount Pathology (Prostatectomy)				
Targeted MR/Ultrasound Fusion Biopsy Results	Low-Risk Cancer	Intermediate-Risk Cancer	High-Risk Cancer	Totals	
No cancer	Standard biopsy resultsNo cancer0Low6Intermediate7High1	Standard biopsy results         No cancer       0         Low       0         Intermediate       1         High       0	Standard biopsy results         No cancer       0         Low       0         Intermediate       1         High       1	17	
Low-risk cancer	Standard biopsy resultsNo cancer4Low27Intermediate7High0	Standard biopsy resultsNo cancer2Low9Intermediate2High0	Standard biopsy resultsNo cancer1Low2Intermediate1High2	57	
Intermediate-risk cancer	Standard biopsy resultsNo cancer3Low8Intermediate8High1	Standard biopsy resultsNo cancer2Low7Intermediate4High0	Standard biopsy results         No cancer       0         Low       2         Intermediate       2         High       1	38	
High-risk cancer	Standard biopsy resultsNo cancer1Low1Intermediate0High2	Standard biopsy resultsNo cancer0Low3Intermediate2High3	Standard biopsy resultsNo cancer7Low9Intermediate4High26	58	
Totals	76	35	59	170	



Performance of Different Biopsy Approaches in the Detection of Intermediate- toHigh-Risk Prostate Cancer on Whole-Gland Prostatectomy Specimen

	Targeted MR/Ultrasound Fusion Biopsy	Standard Extended-Sextant Biopsy	Combined Biopsy
Sensitivity, % (95% CI)	77 (67-84)	53 (43-63)	85 (76-91)
Specificity, % (95% CI)	68 (57-78)	66 (54-76)	49 (37-60)
Negative predictive value, % (95% CI)	70 (58-80)	53 (43-63)	73 (58-84)
Positive predictive value, % (95% CI)	75 (65-83)	66 (54-76)	67 (58-75)
Accuracy, % (95% CI)	73 (70-76)	59 (55-63)	69 (65-72)
AUC (95% CI)	0.73 (0.66-0.79)	0.59 (0.52-0.67)	0.67 (0.60-0.74)
<i>P</i> value of comparison with targeted MR/ ultrasound biopsy		.005	.04



The utility of standard biopsy in addition to targeted biopsy was limited

- The number needed to biopsy (standard template) to diagnose 1 additional high-risk tumor was 200 men
- For every 1 high-risk tumor diagnosed, 17 additional low-risk tumors would also be diagnosed

Limitation: referral bias, patients with MRI lesions **and** prior -ve biopsy



Andrew B. Rosenkrantz,\*,† Sadhna Verma, Peter Choyke, Steven C. Eberhardt, Scott E. Eggener,‡ Krishnanath Gaitonde, Masoom A. Haider, Daniel J. Margolis, Leonard S. Marks, Peter Pinto, Geoffrey A. Sonn and Samir S. Taneja§

#### QUALITY ASSURANCE

- Experienced radiologists and biopsy operators
- Ongoing case review, comparing prospective interpretations with histological results



#### MRI Targeted Biopsy Methods

- 1. Cognitive targeting involves estimating the location of a lesion
  - unreliable for lesions that are small or anterior



#### MRI Targeted Biopsy Methods

- 2. MR in-bore target biopsy
  - time-consuming (60 minutes) and labor-intensive
  - concurrent systematic biopsies are not obtained



#### MRI Targeted Biopsy Methods

- 3. MRI/ultrasound fusion guided prostate biopsy
  - familiar approach easily incorporated into existing workflow



**Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal** Ultrasound fusion versus Cognitive Registration.

Is There a Preferred Technique?

			•					
A	n/N			В	Wysock, 2013	n/N 18/22	COG-TB	
Park, 2011	9/13	COG-TB			,	10722	000-15	
Delongchamps, 2013	40/58	00010			Jambor, 2014	21/31		<b>⊢−−−−</b> −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Wysock, 2013	23/39							
Iwamoto, 2014	61 / 106	72%	<b></b>		Pepe, 2015	29/29		<b>-</b>
Boesen, 2014	39/39	/ 2 /0			De	oled random:	85.7 (68.9-94.2)	
Jambor, 2014	22/35				Po	oled random:	05.7 (00.9-94.2)	
Pepe, 2015	29/37		·					
	led random:	72.1 (61.5-80.8)						
100	ica fandom.	12.1 (01.0 00.0)			Vourganti, 2012	40/45	FUS-TB	HH
Miyagawa, 2010	45/52	FUS-TB			Kuru, 2013			
Vourganti, 2012	56/73	10010			Kuru, 2013	104 / 147		
Portalez, 2012	56/62		·		Wysock, 2013	19/22		<b></b>
Kuru, 2013	128 / 200							
Delongchamps, 2013	126 / 149				Shakir, 2014	173 / 192		<b>⊢</b> −− <b>■</b> −1
Wysock, 2013	24/39	81%			Manual 0044			
Fiard, 2013	11/14	01 70	F		Mozer, 2014	66 / 70		F₩1
Shakir, 2014	461 / 564				Salami, 2014	67/72		<b>⊢−−−</b> ∎−1
Salami, 2014	92/113				0			
Mozer, 2014	82/94		II		Rastinehad, 2014	47/51		<b>⊢</b> −−− <b>∎</b> −−1
Salami, 2014	73/91		<b>—</b>		Sonn, 2014	21/25		
Rastinehad, 2014	53/66					21720		
Sonn, 2014	24/36				Po	oled random:	88.8 (82.1-93.2)	
Shoij, 2014	14/14							
Poo	led random:	80.6 (74.9-85.2)	-					
Pokorny, 2014	99 / 117	MRI-TB			Quentin, 2014	58/67	MRI-TB	F€
Quentin, 2014	68/78				Kauffman, 2014	16/16		
Kauffman, 2014	16/16	89%			Radinnan, 2014	16/16		-
Poo	led random:	88.9 (78.4-94.6)			Po	oled random:	92.0 (76.0-97.7)	
	1.1		. T , T , T , T , T , T , T		-	1 4 1	. [ . ] . ]	. 1 . 1 . 1 . 1 . 1 . 1 . 1
	0 10	20 30 40	0 50 60 70 80 90 100			0 10	20 30 40	50 60 70 80 90 100
			Sensitivity (%)				S	ensitivity (%)

Sensitivity (%)

EUROPEAN UROLOGY 71 (2017) 517-531



Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?

#### MRI-GB vs. TRUS-GB

- Equivalent overall PCa detection
- MRI-GB detects more CS-PCa (16%)
- MRI-GB has a lower yield of insignificant PCa (0.47)
- Omitting TRUS-GB would miss 19% of all PCa cases,10% of CS-PCa, and decrease the over diagnosis of insignificant PCa by 50%



Additional Considerations for MRI Targeted Biopsy

1. At least 2 cores from each MRI target



Minimum number of MRI ultrasound fusion targeted biopsy cores needed for prostate cancer detection: Multivariable retrospective lesion-based analyses of patients treated with radical prostatectomy Leyh-Bannurah SR, Kachanov M, Beyersdorff D, Tian Z, Karakiewicz PI, Tilki D, Fisch M, Maurer T, Graefen M, Budäus L

Table 2. Lesion based cumulative percentage of prostate cancer detection per each additional targeted biopsy core that was sampled within 1,459 mpMRI lesions (PI-RADS ≥3) of 771 radical prostatectomy patients

number of targeted biopsy cores sampled per MRI lesion	over	all	syste biopsy (n =	v naïve	≥ 1 pı negat systen biop (n = 5	ive natic sy		ADS 3 110)	PI-RA (n=10		PI-RAI (n=29	
	n	%	n	%	n	200	n	%	n	%	n	%
1	1159	79	741	84	418	73	74	67	830	79	255	87
2	187	92	97	95 💊	90	89	21	86	142	92	24	95
3	84	98	35	99	49	97	10	95	65	98	9	98
≥4	29	100	13	100	16	100	5	100	18	100	6	100

A.

J Urol Aug 2019



Additional Considerations for MRI Targeted Biopsy

- 2. Systematic and MRI targeted cores be separately labeled
  - pathologist to report the presence of inflammation, HGPIN and ASAP
  - correlative histological abnormality may provide assurance that targeting was accurate when the lesion is benign



Concurrent Systematic Sampling when Performing MRI Targeting

- CS-PCa detected by systematic biopsies and missed by targeted biopsy (0% to 23%)
  - repeat biopsies vs. biopsy-naive



#### MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Quality of Life and Safety

- no difference between groups
- no difference WRT discomfort or pain
- better in the MRI-targeted group at 30 days:
  - \* hematuria (30% vs. 63%)
  - \* hematospermia (32% vs. 60%)
  - \* rectal bleeding (14% vs. 22%)
  - \* pain (13% vs. 23%)
  - \* erectile dysfunction (11% vs. 16%)
  - \* serious adverse events (2% vs. 2%)



## Infections and hospitalizations

the lower incidence among patients undergoing MRI-targeted prostate biopsy appears related to trans-perineal access rather than the number of cores taken

EUROPEAN UROLOGY 71 (2017) 353-365



Role of Immediate Re-biopsy after MRI

- Target biopsy PIRAD 4 or 5 lesions, and likely 3
  - continue followup, as 5% 15% of CS-PCa remain undetected on MRI
  - serial PSA, DRE and repeat MRI



#### Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial

Laurence Klotz<sup>*a*,\*</sup>, Andrew Loblaw<sup>*a*</sup>, Linda Sugar<sup>*b*</sup>, Madeline Moussa<sup>*c*</sup>, David M. Berman<sup>*d*</sup>, Theo Van der Kwast<sup>*e*</sup>, Danny Vesprini<sup>*a*</sup>, Laurent Milot<sup>*b*</sup>, Marlene Kebabdjian<sup>*b*</sup>, Neil Fleshner<sup>*f*</sup>, Sangeet Ghai<sup>*f*</sup>, Joe Chin<sup>*c*</sup>, Gregory R. Pond<sup>*g*</sup>, Masoom Haider<sup>*b*</sup>


Under-treatment: AS may miss clinically significant prostate cancers

- 25% harbour aggressive tumor at radical prostatectomy
- high risk disease often located anteriorly

Over-treatment and morbidity of repeat biopsy



#### Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial





# mp-MRI Health Economics

Cost savings over standard TRUS-guided biopsy may emerge:

- earlier detection of clinically significant cancers
- fewer cases of insignificant cancer diagnosed
- fewer repeat biopsies



## Full PI-RADS-compliant protocol

 T2- weighted imaging (T2WI) in 3 orthogonal planes
 after iv contrast, diffusion-weighted imaging (DWI)
 and dynamic contrast-enhanced (DCE), reserved for the clarification of equivocal abnormalities in the peripheral zone

Short, non-contrast bi-parametric MRI (bp-MRI) may be safer, faster, cheaper and expand usage:

- 1. T2WI
- 2. DWI



### High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility

Marloes van der Leest<sup>a,†,\*</sup>, Bas Israël<sup>a,b,†</sup>, Erik Bastiaan Cornel<sup>c</sup>, Patrik Zámecnik<sup>a</sup>, Ivo G. Schoots<sup>d</sup>, Hans van der Lelij<sup>e</sup>, Anwar R. Padhani<sup>f</sup>, Maroeska Rovers<sup>g</sup>, Inge van Oort<sup>b</sup>, Michiel Sedelaar<sup>b</sup>, Christina Hulsbergen-van de Kaa<sup>h</sup>, Gerjon Hannink<sup>g</sup>, Jeroen Veltman<sup>i,‡</sup>, Jelle Barentsz<sup>a,‡</sup>

Sequence	mp-MRI	bp-MRI	"Fast" bp-MRI
T2WI localizers	0:00:51	0:00:51	0:00:26
T2WI localizer (sagittal)	0:00:07	0:00:07	0:00:00 *
T2WI sagittal	0:02:31	0:02:31	0:00:00
T2WI coronal	0:02:15	0:02:15	0:00:00 *
T2WI transversal	0:02:33	0:02:33	0:02:33
DWI	0:04:50	0:04:50	0:04:50
DCE imaging	0:02:50	0:00:00	0:00:00
Total sequence time	0:15:57	0:13:07	0:07:49


bp = biparametric; DCE = dynamic contrast enhanced; DWI = diffusion weighted imaging; mp = multiparametric; MRI = magnetic resonance imaging; T2WI = T2-weighted imaging.



### High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility

	Sensitivity % (95% CI)	Specificity % (95% CI)	NPV % (95% CI)	PPV % (95% CI)	LR– (95% CI)	LR+ (95% CI)
mp-MRI	95 (91–97)	69 (64–73)	97 (94–98)	57 (51-62)	0.077 (0.042-0.14)	3.0 (2.6-3.5)
bp-MRI	95 (91-97)	69 (64-73)	97 (94-98)	57 (51-62)	0.077 (0.042-0.14)	3.0 (2.6-3.5)
"Fast" bp-MRI	95 (91–97)	65 (61-70)	97 (94–98)	54 (49-60)	0.081 (0.044-0.15)	2.7 (2.4–3.1)
bp = biparametric; LR- = negative likelihood ratio; LR+ = positive likelihood ratio; mp = multiparametric; MRI = magnetic resonance imaging; NPV = negative						

predictive value; PPV = positive predictive value.





Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

Evidence up to July 2018, 43 studies, 13,770 men

- Out of 1000 men at risk for PCa, MRI will correctly identify 273 out of 300 who actually have CS-PCa (Sn 91%), but miss 27 men
- Of the remaining 700 men, MRI will correctly identify 259 as not having PCa, but will misclassify 441 men as having CS-PCa (Sp 37%)



Cochrane Database of Systematic Reviews



Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

In the same population MR-targeted biopsy,

- Out of 300 men with CS-PCa, will correctly identify 240 (Sn 80%), but miss 60
- Of the remaining 700 men without CS-PCa, will correctly identify 658 (Sp 94%), but misclassify 42 as having CS-PCa



Cochrane Database of Systematic Reviews



Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

In the same population systematic biopsy,

- Out of 300 men with CS-PCa, will correctly identify 189 (Sn 63%), but miss 111
- Of the 700 men without CS-PCa, all will be correctly identified (Sp 100%)



Cochrane Database of Systematic Reviews



Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG

mp-MRI performance compared to systematic biopsy (detection ratio)

- 1.12 for ISUP grade  $\geq 2$ 
  - # 1.44 in patients with prior negative biopsy
  - 1.05 in biopsy-naive
- 1.2 for ISUP grade  $\geq$  3
  - 1.64 in patients with prior negative biopsy
  - 1.09 in biopsy-naive





## 2019 EAU Guidelines

Recommendations in patients with prior negative biopsy	LE	Strength rating
Perform mpMRI before prostate biopsy	1a	Strong
When mpMRI is positive (i.e. PI-RADS ≥ 3), perform targeted biopsy only.	2a	Weak
When mpMRI is negative (PI-RADS $\leq$ 2), and clinical suspicion of prostate cancer is high, perform systematic biopsy	2a	Strong



## 2019 EAU Guidelines

Recommendations in men on active surveillance	LE	Strength rating
Perform mpMRI before a confirmatory prostate biopsy, if not done before the first biopsy.	1a	Strong
Perform the combination of targeted biopsy (of any PI-RADS ≥ 3 lesion) and systematic biopsy at confirmatory biopsy.	2a	Weak






Hashim U Ahmed\*, Ahmed El-Shater Bosaily\*, Louise C Brown\*, Rhian Gabe, Richard Kaplan, Mahesh K Parmar, Yolanda Collaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex P Kirkham, Robert Oldroyd, Chris Parker, Mark Emberton, and the PROMIS study group†

The reference test was template prostate mapping (TPM):

- core biopsies of the entire prostate taken every 5 mm
- centrally reported by expert uropathologists
- blinded to MR images and TRUS-biopsy findings
- Clinically significant prostate cancer:
- Gleason ≥4 + 3
- or core length ≥6 mm




Hashim U Ahmed\*, Ahmed El-Shater Bosaily\*, Louise C Brown\*, Rhian Gabe, Richard Kaplan, Mahesh K Parmar, Yolanda Collaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex P Kirkham, Robert Oldroyd, Chris Parker, Mark Emberton, and the PROMIS study group†





Hashim U Ahmed\*, Ahmed El-Shater Bosaily\*, Louise C Brown\*, Rhian Gabe, Richard Kaplan, Mahesh K Parmar, Yolanda Collaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex P Kirkham, Robert Oldroyd, Chris Parker, Mark Emberton, and the PROMIS study group†





Hashim U Ahmed\*, Ahmed El-Shater Bosaily\*, Louise C Brown\*, Rhian Gabe, Richard Kaplan, Mahesh K Parmar, Yolanda Collaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex P Kirkham, Robert Oldroyd, Chris Parker, Mark Emberton, and the PROMIS study group†

	MP-MRI, % (95% CI)	TRUS-biopsy, % [95% Cl]	Test ratio* [95% CI]	p value
Primary definition (Gleason score ≥4+3 or cancer core length ≥6 mm), prevalence of clinically significant cancer 230 (40%, 36–44%)				
Sensitivity test	93 (88–96)	48 (42–55)	0.52 (0.45–0.60)	p<0.0001
Specificity test	41 (36–46)	96 (94–98)	2·34 (2·08–2·68)	p<0.0001
PPV	51 (46–56)	90 (83–94)	8.2 (4.7–14.3)	p<0.0001
NPV	89 (83–94)	74 (69–78)	0·34 (0·21–0·55)	p<0.0001
Any Gleason score 7 (≥3+4), prevalence of clinically significant cancer 308 (53%, 49–58%)				
Sensitivity test	88 (84–91)	48 (43–54)	0.55 (0.49–0.62)	p<0.0001
Specificity test	45 (39–51)	99 (97–100)	2·22 (1·94–2·53)	p<0.0001
PPV	65 (60–69)	99 (95–100)	40.8 (10.2–162.8)	p<0.0001
NPV	76 (69–82)	63 (58–67)	0.53 (0.38–0.73)	p<0.0001



# Is MRI The Ideal Triage Test

mpMRI has a high negative predictive value (NPV):

- one-quarter of men would avoid prostate biopsy
- minimize over-diagnosis
- side-effects of over-treatment
- burden of active surveillance on patients and system

Low specificity and PPV means that biopsy is still needed target or systematic?



# **MR-Targeted Biopsy Alone**

A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy

Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer





# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

MAY 10, 2018

VOL. 378 NO. 19

### MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Virdi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*

### PRECISION

PRostate Evaluation for Clinically Important disease: Sampling using Image guidance Or Not



V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Virdi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*

#### Screening population:

- no prior biopsy
- elevated PSA (≤20) &/or +ve DRE (≤T2)

Table 1. Characteristics of the Participants at Baseline.*				
Characteristic	MRI-Targeted Biopsy Group (N=252)	Standard-Biopsy Group (N=248)		
Age — yr	64.4±7.5	64.5±8.0		
PSA level — ng/ml				
Median	6.75	6.50		
Interquartile range	5.16-9.35	5.14-8.65		
Family history of prostate cancer — no. (%)	48 (19)	40 (16)		
Abnormal digital rectal examination — no. (%)	36 (14)	38 (15)		

N Engl J Med 2018;378:1767-77.



V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Virdi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*

#### Screening population: • no prior biopsy

N Engl J Med 2018;378:1767-77.

elevated PSA (≤20) &/or +ve DRE (≤T2)

Table 1. Characteristics of the Participants at Baseline.*				
Characteristic	MRI-Targeted Biopsy Group (N=252)	Standard-Biopsy Group (N = 248)		
Age — yr	64.4±7.5	64.5±8.0		
PSA level — ng/ml				
Median	6.75	6.50		
Interquartile range	5.16-9.35	5.14-8.65		
Family history of prostate cancer — no. (%)	48 (19)	40 (16)		
Abnormal digital rectal examination — no. (%)	36 (14)	38 (15)		




Outcome	MRI-Targeted Biopsy Group (N=252)	Standard-Biopsy Group (N = 248)
Biopsy outcome — no. (%)		
No biopsy because of negative result on MRI	71 (28)	0
Benign tissue	52 (21)	98 (40)
Atypical small acinar proliferation	0	5 (2)
High-grade prostatic intraepithelial neoplasia	4 (2)	10 (4)
Gleason score		
3+3	23 (9)	55 (22)
3+4	52 (21)	35 (14)
3+5	2 (1)	l (<1)
4+3	18 (7)	19 (8)
4+4	13 (5)	6 (2)
4+5	7 (3)	2 (1)
5+5	3 (1)	l (<1)
No biopsy <u>‡</u>	4 (2)	3 (1)
Withdrawal from trial§	3 (1)	13 (5)

N Engl J Med 2018;378:1767-77.



V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Virdi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*



N Engl J Med 2018;378:1767-77.



V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Virdi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*

#### Clinically significant prostate cancer defined as Gleason score $\ge$ 3+4

Outcome	MRI-Targeted Biopsy Group (N = 252)	Standard-Biopsy Group (N = 248)	Difference†	P Value
Clinically significant cancer¶				
Intention-to-treat analysis — no. (%)	95 (38)	64 (26)	12 (4 to 20)	0.005
Modified intention-to-treat analysis — no./total no. (%)	95/245 (39)	64/235 (27)	12 (3 to 20)	0.007
Per-protocol analysis — no./total no. (%)	92/235 (39)	62/227 (27)	12 (3 to 20)	0.007
Clinically insignificant cancer — no. (%)	23 (9)	55 (22)	-13 (-19 to -7)	< 0.001
Maximum cancer core length — mm	7.8±4.1	6.5±4.5	1.0 (0.0 to 2.1)	0.053
Core positive for cancer — no./total no. of cores (%)	422/967 (44)	515/2788 (18)		_
Men who did not undergo biopsy — no. (%) $\ $	78 (31)	16 (6)	_	—
			N Engl J Med 2018;	378:1767-77.



V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Virdi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*

#### Further management

- standard group 39 (16%) >> 38 (15%) mp-MRI
   >> repeat biopsy 9 >> 3 clinically significant cancer
- MRI group 7 (3%) >> 3 (1%) standard biopsy
   > all negative